Improved therapeutic responses for liposomal doxorubicin targeted via thrombospondin peptidomimetics versus untargeted doxorubicin

Journal of Peptide Science

Volumn 16, Issue 7, 2010, Pages 315-321

  Rivera Fillat, M P ^a   Reig, F ^b   Martinez E M ^a   Grau Oliete, M R ^a  

^a CSIC   (Spain)

^b INSTITUTE OF ADVANCED CHEMISTRY OF CATALONIA IQAC CSIC   (Spain)

Author keywords

Angiogenesis; Liposomal doxorubicin; Peptide analogs; Targeting; Thrombospondin

Indexed keywords

DOXORUBICIN; LIPOSOME; PEPTIDOMIMETIC AGENT; THROMBOSPONDIN 1; THROMBOSPONDIN 2; ANGIOGENESIS INHIBITOR; DRUG CARRIER; THROMBOSPONDIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL ADHESION; CELL STRAIN HT29; CHICK EMBRYO; CHORIOALLANTOIS; CONTROLLED STUDY; DRUG TARGETING; EMBRYO; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; LIPOSOMAL DELIVERY; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; TUMOR XENOGRAFT; ANIMAL; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECTS; DRUG SCREENING; MOLECULAR MIMICRY; NEOVASCULARIZATION, PATHOLOGIC; PROCEDURES; TUMOR CELL LINE;

MUS MUSCULUS;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL ADHESION; CELL LINE, TUMOR; DOXORUBICIN; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; ENDOTHELIAL CELLS; HUMANS; LIPOSOMES; MICE; MICE, NUDE; MOLECULAR MIMICRY; NEOVASCULARIZATION, PATHOLOGIC; THROMBOSPONDINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77954717679     PISSN: 10752617     EISSN: 10991387     Source Type: Journal    
DOI: 10.1002/psc.1241     Document Type: Article

References (19)

1. Eberhard A, Kahlert E, Goede V, Hemmerlein B, Plate KH, Augustin HG. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res. 2000; 60: 1388-1393. (Pubitemid 30152012)
2. Hahnfeldt P, Panigrahy D, Folkman J, Hlatky L. Tumor development under angiogenic signaling: a dinamical theory of tumor growth, treatment response, and postvascular dormancy. Cancer Res. 1999; 59: 4770-4775. (Pubitemid 29472873)
3. Corti A, Ponzoni M. Tumor vascular targeting with tumor necrosis factor alpha and chemotherapeutic drugs. Ann. N Y Acad. Sci. 2004; 1028: 104-112. (Pubitemid 40361814)
4. Maeda N, Takeuchi Y, Takada M, Sadzuka Y, Namba Y, Oku N. Anti-neovascular therapy by use of tumor neovasculature-targeted long-circulating liposome. J. Control. Release 2004; 100: 41-52. (Pubitemid 39445984)
5. Pastorino F, Brignole C, Marimpietri D. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. Cancer Res. 2003; 63: 7400-7409.
6. Chen H, Herndon ME, Lawler J. The cell biology of thrombospondin- 1. Matrix Biol. 2000; 19: 597-614.
7. Guo N-H, Krutzsch HC, Inman JK, Roberts DD. Thrombospondin 1 and type 1 repeat peptides of thrombospondin 1 specifically induce apoptosis of endothelial cells. Cancer Res. 1997; 57: 1735-1742.
8. Iruela-Arispe ML, Lombardo M, Krutzsch HC, Lawler J, Roberts DD. Inhibition of angiogenesis by thrombospondin-1 is mediated by two independent regions within the type 1 repeats. Circulation 1999; 100: 1423-1431. (Pubitemid 29451703)
9. Murphy-Ullrich JE, Poczatec M. Activation of latent TGF-β by thrombospondin-1: mechanisms and physiology. Cytokine Growth Factor Rew. 2000; 11: 59-69.
10. Schultz-Cherry S, Chen J, Mosher DF, Misenheimer TM, Krutzsch HC, Roberts DD, Murphy-Ullrich JE. Regulation of transforming growth factor-β activation by discrete sequences of thrombospondin 1. J. Biol. Chem. 1995; 270: 7304-7310.
11. Guo NH, Krutzsch HC, Inman JK, Shannon CS, Roberts DD. Antiproliferative and antitumor activities of D-reverse peptides derived from the second type-1 repeat of thormbospondin 1. J. Pept. Res. 1997; 50: 210-221.
12. Cebrian J, Grau-Oliete MR, Rivera-Fillat MP, Reig F. Synthesis and biological activity of thrombospondin related peptides. Curr. Topics Pept. Protein Res. 2001; 4: 81-88.
13. Cebrián J, Domingo V, Reig F. Synthesis of peptide sequences related tothrombospondin:factorsaffectingaspartimideby-product formation. J. Pept. Res. 2003; 62: 238-244. (Pubitemid 37521903)
14. Bogdanov AA Jr, Klibanov AL, Torchilin VP. Protein immobilization on the surface of liposomes via carbodiimide in presence of N-hydroxysulfosuccinimide. FEBS Lett. 1988; 231: 381-384.
15. Casas J, Gorchs F, Sánchez-Baeza P, Teixidor P, Messeguer A. Inhibition of rat liver microsomal lipid peroxidation elicited by simple 2,2-dimethylcromenes and chromans structurally related to precocenes. J. Agric. Food Chem. 1992; 40: 585-590.
16. Almiñana N, Polo D, Rodriguez L, Reig F. Biodistribution study of doxorubicin encapsulated in liposomes: influence ofpeptide coating and lipid composition. Prep. Biochem. Biotech. 2004; 34: 77-96. (Pubitemid 38319296)
17. Skehan P, Storneg R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 1990; 82: 1107-1112. (Pubitemid 20213250)
18. Hanahan D, Bergers G, Bergsland E. Less is more, regularly metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J. Clin. Invest. 2000; 105: 1047-7.
19. Lennernäs B, Albertsson P, Lennernäs H, Norrby K. Chemotherapy and antiangiogenesis. Drug-specific, dose-related effects. Acta Oncol. 2003; 42: 294-303. (Pubitemid 36851146)